+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Atrial Fibrillation - Pipeline Review, H2 2020

  • ID: 5146898
  • Drug Pipelines
  • August 2020
  • Region: Global
  • 134 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Acesion Pharma Aps
  • ARCA biopharma Inc
  • Chaperone Pharma BV
  • Espero BioPharma Inc
  • InCarda Therapeutics Inc
  • Nissan Chemical Corp
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Atrial Fibrillation - Pipeline Review, H2 2020, provides an overview of the Atrial Fibrillation (Cardiovascular) pipeline landscape.

Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain. The predisposing factors include age, heart disease, high blood pressure, family history and drinking alcohol. Treatments for atrial fibrillation may include medications and surgery.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Atrial Fibrillation - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Atrial Fibrillation (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atrial Fibrillation (Cardiovascular) pipeline guide also reviews the key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 8, 6, 1, 11, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Atrial Fibrillation (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atrial Fibrillation (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Atrial Fibrillation (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Atrial Fibrillation (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Atrial Fibrillation (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Atrial Fibrillation (Cardiovascular)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Atrial Fibrillation (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Atrial Fibrillation (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Acesion Pharma Aps
  • ARCA biopharma Inc
  • Chaperone Pharma BV
  • Espero BioPharma Inc
  • InCarda Therapeutics Inc
  • Nissan Chemical Corp
Introduction
  • Atrial Fibrillation - Overview
  • Atrial Fibrillation - Therapeutics Development
Atrial Fibrillation - Therapeutics Assessment

Atrial Fibrillation - Companies Involved in Therapeutics Development

Atrial Fibrillation - Drug Profiles

Atrial Fibrillation - Dormant Projects
  • Atrial Fibrillation - Discontinued Products
  • Atrial Fibrillation - Product Development Milestones
Appendix

List of Tables
  • Number of Products under Development for Atrial Fibrillation, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Atrial Fibrillation - Pipeline by Acesion Pharma Aps, H2 2020
  • Atrial Fibrillation - Pipeline by Allergan Ltd, H2 2020
  • Atrial Fibrillation - Pipeline by Allosteros Therapeutics Inc, H2 2020
  • Atrial Fibrillation - Pipeline by AnaBios Corp, H2 2020
  • Atrial Fibrillation - Pipeline by ARCA biopharma Inc, H2 2020
  • Atrial Fibrillation - Pipeline by Armaron Bio Pty Ltd, H2 2020
  • Atrial Fibrillation - Pipeline by Bayer AG, H2 2020
  • Atrial Fibrillation - Dormant Projects, H2 2020
  • Atrial Fibrillation - Dormant Projects, H2 2020 (Contd..1), H2 2020
  • Atrial Fibrillation - Dormant Projects, H2 2020 (Contd..2), H2 2020
  • Atrial Fibrillation - Discontinued Products, H2 2020
  • Atrial Fibrillation - Discontinued Products, H2 2020 (Contd..1), H2 2020
List of Figures
  • Number of Products under Development for Atrial Fibrillation, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • Acesion Pharma Aps
  • Allergan Ltd
  • Allosteros Therapeutics Inc
  • AnaBios Corp
  • ARCA biopharma Inc
  • Armaron Bio Pty Ltd
  • Bayer AG
  • Chaperone Pharma BV
  • Chong Kun Dang Pharmaceutical Corp
  • Correvio Pharma Corp
  • Daiichi Sankyo Co Ltd
  • Espero BioPharma Inc
  • FB HRS LLC
  • G3 Pharmaceuticals Inc
  • HUYA Bioscience International LLC
  • Hyloris Pharmaceuticals SA
  • InCarda Therapeutics Inc
  • Merck & Co Inc
  • Merz Pharma GmbH & Co KgaA
  • Milestone Pharmaceuticals Inc
  • MyoKardia Inc
  • Nissan Chemical Corp
  • Novartis AG
  • OMEICOS Therapeutics GmbH
  • Rhythm Therapeutics Inc
  • Rithim Biologics Inc
  • The Geneva Biotech Center SA
  • Toa Eiyo Ltd
  • Verseon Corp
  • Vivasc Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll